Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Protocol Amendment History 3 changes
notable Trial sites expanded: 78 -> 91 locations 2026-07-21
notable Trial sites expanded: 72 -> 78 locations 2026-06-27
minor Trial arms changed: 10 -> 9 2026-05-27
Trial Details
NCT Number NCT07293351
Lead Sponsor Bristol-Myers Squibb
Collaborators: BioNTech SE
Conditions Advanced Renal Cell Carcinoma (RCC)
Enrollment 254 participants
Start Date 2026-03-26
Primary Completion 2029-11-28 (estimated)
Study Completion 2031-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-30